Hainsworth J D, Jolivet J, Birch R, Hopkins L G, Greco F A
Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA.
Cancer. 1997 Feb 15;79(4):740-8.
Previous Phase II studies using the combination of mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast carcinoma have shown this regimen to be active and well tolerated. In this randomized Phase II study, the authors compared the NFL regimen with a standard CMF regimen in the first-line therapy of patients with metastatic breast carcinoma.
One hundred twenty-eight women receiving their first chemotherapy for metastatic breast carcinoma were entered into this randomized study. Sixty-four patients were treated with NFL: mitoxantrone 12 mg/m2 IV on Day 1; leucovorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding administration of 5-fluorouracil; and 5-fluorouracil 350 mg/m2 IV bolus on Days 1, 2, and 3. Sixty-four patients received CMF: cyclophosphamide 600 mg/m2 IV on Day 1; methotrexate 40 mg/m2 IV on Day 1; and 5-fluorouracil 600 mg/m2 IV on Day 1. Both regimens were repeated at 21-day intervals; responding patients received at least 8 courses.
Patients treated with NFL had a higher response rate than patients treated with the CMF regimen (45% vs. 26%, respectively; P = 0.021). Median duration of response was 9 months with NFL and 6 months with CMF (P = 0.10); 11 patients had long responses (>12 months) with NFL versus 4 patients with CMF (P = 0.06). Median survival was similar for both groups. Both regimens were well tolerated, with infrequent Grade 3 or 4 toxicities.
NFL is an active, well-tolerated regimen for the treatment of metastatic breast carcinoma; it produced a higher response rate than the CMF regimen used in this study. Although more intense CMF regimens or regimens containing doxorubicin would likely increase the response rate, they would almost certainly do so with the consequence of greater toxicity as compared with NFL. NFL is an excellent initial palliative treatment option for elderly patients or patients who have exhibited poor tolerance for other chemotherapy regimens.
先前使用米托蒽醌、5-氟尿嘧啶和高剂量亚叶酸(NFL)联合治疗转移性乳腺癌的II期研究表明,该方案具有活性且耐受性良好。在这项随机II期研究中,作者比较了NFL方案与标准CMF方案在转移性乳腺癌患者一线治疗中的效果。
128名接受转移性乳腺癌首次化疗的女性患者进入该随机研究。64名患者接受NFL治疗:第1天静脉注射米托蒽醌12mg/m²;在第1、2、3天,于注射5-氟尿嘧啶前30 - 60分钟静脉注射亚叶酸300mg;第1、2、3天静脉推注5-氟尿嘧啶350mg/m²。64名患者接受CMF治疗:第1天静脉注射环磷酰胺600mg/m²;第1天静脉注射甲氨蝶呤40mg/m²;第1天静脉注射5-氟尿嘧啶600mg/m²。两种方案均每21天重复一次;有反应的患者至少接受8个疗程。
接受NFL治疗的患者的缓解率高于接受CMF方案治疗的患者(分别为45%对26%;P = 0.021)。NFL治疗的中位缓解持续时间为9个月,CMF为6个月(P = 0.10);11名接受NFL治疗的患者有长期缓解(>12个月),而接受CMF治疗的为4名患者(P = 0.06)。两组的中位生存期相似。两种方案耐受性均良好,3级或4级毒性反应少见。
NFL是一种用于治疗转移性乳腺癌的活性良好且耐受性佳的方案;它产生的缓解率高于本研究中使用的CMF方案。尽管更强的CMF方案或含阿霉素的方案可能会提高缓解率,但与NFL相比,几乎肯定会带来更大的毒性。对于老年患者或对其他化疗方案耐受性差的患者,NFL是一种极佳的初始姑息治疗选择。